IRIS
BUTTITTA, Fiamma
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.342
EU - Europa 3.028
AS - Asia 1.900
SA - Sud America 131
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
Totale 8.423
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.310
SG - Singapore 783
CN - Cina 619
UA - Ucraina 537
IE - Irlanda 481
IT - Italia 463
GB - Regno Unito 387
SE - Svezia 382
TR - Turchia 312
FR - Francia 285
DE - Germania 199
BR - Brasile 120
FI - Finlandia 105
IN - India 104
RU - Federazione Russa 95
CZ - Repubblica Ceca 22
CA - Canada 21
BE - Belgio 20
HK - Hong Kong 17
NL - Olanda 12
AT - Austria 11
VN - Vietnam 11
IL - Israele 8
EU - Europa 7
JP - Giappone 7
MX - Messico 7
PK - Pakistan 7
TW - Taiwan 7
IR - Iran 6
PL - Polonia 5
MY - Malesia 4
BA - Bosnia-Erzegovina 3
CL - Cile 3
CO - Colombia 3
LB - Libano 3
LT - Lituania 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
UG - Uganda 3
AE - Emirati Arabi Uniti 2
AR - Argentina 2
AU - Australia 2
BD - Bangladesh 2
CH - Svizzera 2
DK - Danimarca 2
DZ - Algeria 2
EE - Estonia 2
ES - Italia 2
MA - Marocco 2
RO - Romania 2
BY - Bielorussia 1
CR - Costa Rica 1
EC - Ecuador 1
EG - Egitto 1
GR - Grecia 1
IQ - Iraq 1
JM - Giamaica 1
KR - Corea 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MN - Mongolia 1
NI - Nicaragua 1
NP - Nepal 1
PE - Perù 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
SV - El Salvador 1
TH - Thailandia 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 8.423
Salva come PNG Salva come JPEG
Città #
Chandler 653
Jacksonville 610
Singapore 562
Dublin 471
Southend 264
Princeton 231
Izmir 188
Nanjing 186
Beijing 116
Ashburn 114
Santa Clara 111
Cambridge 101
Dearborn 101
The Dalles 90
Wilmington 90
Altamura 71
Boardman 70
Ann Arbor 67
Chieti 60
Nanchang 57
Pescara 49
Shenyang 49
New York 47
Los Angeles 37
Tianjin 29
Hangzhou 26
Hebei 26
Woodbridge 26
Rome 25
Kunming 23
Munich 22
Grevenbroich 21
Milan 21
Washington 21
Augusta 16
Brussels 16
Jiaxing 15
Toronto 15
Hong Kong 14
Jinan 14
Norwalk 14
San Mateo 14
Brno 13
Collecorvino 12
Helsinki 12
Ningbo 12
Orange 11
Changsha 9
Nuremberg 9
São Paulo 9
Dong Ket 8
Latina 8
London 8
Montesilvano 8
Vienna 8
Auburn Hills 7
Olomouc 7
Ancona 6
Belo Horizonte 6
Falls Church 6
Guangzhou 6
Lanzhou 6
Tappahannock 6
Varallo 6
Chennai 5
Fairfield 5
Leawood 5
Mexico City 5
Zhengzhou 5
Ascoli Piceno 4
Boston 4
Changchun 4
Chicago 4
Edinburgh 4
Frankfurt am Main 4
Hanover 4
Houston 4
Kuala Lumpur 4
Turku 4
Verona 4
Andover 3
Antwerp 3
Brooklyn 3
Cavacurta 3
Charlotte 3
Civitanova Marche 3
Council Bluffs 3
Gloucester 3
Kampala 3
New Delhi 3
Oslo 3
Ottawa 3
Seattle 3
Squinzano 3
Stockholm 3
Taichung 3
Taizhou 3
Valduggia 3
Bari 2
Bauru 2
Totale 5.063
Salva come PNG Salva come JPEG
Nome #
Assessing EGFR mutations. 156
ALK protein analysis by IHC staining after recent regulatory changes: A comparison of two widely used approaches, revision of the literature, and a new testing algorithm 138
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays 136
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. 126
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment 122
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: Results of the first italian external quality assurance scheme 118
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors 115
A unique microRNA signature associated with plaque instability in humans. 111
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 108
A unique microRNA signature associated with ischemic stroke in humans 107
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle 107
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. 104
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 104
ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm 100
ATP-binding cassette transporter A1 (ABCA1) overexpression in hypercholesterolemic plaques: a potential molecular explanation 98
Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. 98
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 96
Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control 95
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 92
AKT1(E17K) in human solid tumours 91
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 90
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. 90
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 90
Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. 88
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. 88
Overexpression of ABCA1 in human plaques exposed to hypercholesterolemia: the role of microRNA modulation 88
Reduction of atherothrombotic burden before stent deployment in non-ST elevation acute coronary syndromes: Reduction of myocardial necrosis achieved with nose-dive manual thrombus aspiration (REMNANT) trial. A volumetric intravascular ultrasound study 88
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. 86
The chromosomal location of the mouse mammary tumor gene Int6 and related pseudogenes in the mouse genome. 85
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. 85
Hypertension is a determinant of ABCA1 expression in atherosclerotic plaques from hypercholesterolemic patients 85
p53 alterations in non-small cell lung cancer correlate with metastatic involvement of hilar and mediastinal lymph nodes 84
Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up 84
ABCA-1 expression is reduced in atherosclerotic plaques from hypertensive patients: a new potential link between hypertension and atherosclerosis 84
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. 84
Enriched SSCP: a highly sensitive method for the detection of unknown mutations. Application to the molecular diagnosis of lung cancer in sputum samples. 83
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation 83
Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. 83
Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. 82
Correspondence - In Reply - Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting 82
mdm2 gene alterations and mdm2 protein expression in breast carcinomas 82
Mutational profile of GNAQQ209 in human tumors. 82
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 82
Host genetic background effect on the frequency of mouse mammary tumor virus-induced rearrangements of the int-1 and int-2 loci in mouse mammary tumors. 81
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. 80
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. 80
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 80
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. 79
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 78
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies 78
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. 77
Association between cigarette smoking and FHIT gene alterations in lung cancer. 77
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy 77
Bronchioloalveolar carcinoma: K-ras mutations are constant events in the mucinous subtype 76
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. 76
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 76
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 76
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. 76
Telomerase activity as a prognostic indicator in Stage I Non- Small Cell Lung Cancer -Gruppo Italiano di Patologia Molecolare II Riunione Scientifica. Pisa 20-22 Giugno99 75
Survivin gene expression in early-stage non-small cell lung cancer. 75
The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. 73
Hypertension modulates miR-145 expression in human atherosclerotic plaques 73
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. 72
microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer. 72
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 72
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. 72
mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. 71
Genetic analysis of lung tumors of non-smoking subject: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus 71
Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. 71
Predictive markers in lung cancer: A few hints for the practicing pathologist 71
Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations 71
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments 70
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients 70
Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. 69
Detection of gene mutations on cytological specimens: clinical implications 69
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 69
Stabilita’ del dna in campioni citologici conservati in fase liquida 68
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 67
Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. 66
Telomerase Activity as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer 66
Evaluation of FHIT gene alterations in ovarian cancer 64
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. 63
POLE exonuclease domain mutations in endometrial carcinoma: a case report 62
Reduced expression of INT-6/eIF3-p48 in human tumors. 61
null 61
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. 59
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. 59
Nucleotide and deduced amino acid sequences of tumor gene INT6. 59
p53 mutations and histologic type of invasive breast carcinoma. A polymerase chain reaction-single-strand conformation polymorphism and immunohistochemical analysis. 58
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients 58
p53 mutations and histological type of invasive breast carcinoma. 57
p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. 56
Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. 54
Prostatic cancer: molecular bases. 54
p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. 52
p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study 51
Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. 50
Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. 50
Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. 50
Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. 46
Totale 8.024
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.875
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.875
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020167 0 0 0 0 0 0 0 0 0 0 156 11
2020/2021663 114 8 119 5 53 132 17 3 77 93 6 36
2021/2022603 18 7 8 131 31 23 13 38 50 33 84 167
2022/20231.709 144 216 70 212 193 345 96 105 233 12 46 37
2023/2024762 68 24 44 23 50 229 153 33 4 27 2 105
2024/20251.781 114 451 376 49 56 74 81 88 235 103 154 0
Totale 8.659